Overview

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
Phase:
Phase 3
Details
Lead Sponsor:
Kodiak Sciences Inc
Treatments:
Aflibercept